Call Now Open
2025 Oxford-Harrington Rare Disease Scholar Award
January 15, 2025
The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, U.K. and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking innovative projects for its 2025 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical...
Continue Reading
September 17, 2024
Progression of acute TBI to chronic neurodegeneration is a major health problem with no protective treatments. Time sensitive inhibition of acutely elevated mitochondrial fission may present a way to protect patients from chronic neurodegeneration. Continue Reading
July 16, 2024
There’s only one U.S. Food and Drug Administration-approved therapy for an inherited retinal disease, and dozens of retinitis pigmentosa (RP) genes for which no therapy is available. Continue Reading
March 25, 2024
Nature Chemical Biology, published March 25, 2024 Continue Reading
March 13, 2024
The rapidly evolving SARS-CoV-2 virus threatens the progress made in curbing the COVID-19 pandemic. A promising novel drug candidate, designed at the atomic level, could help doctors halt the rise of lethal new drug resistant variants. Continue Reading
January 16, 2024
The Jenner Institute is conducting a new study, using BCG, the current licensed vaccine against tuberculosis. Continue Reading
December 21, 2023
The study showed that all doses of ALX-001 were well tolerated, up to and including levels high enough to achieve full brain target engagement, supporting the company’s plans to continue clinical development for the treatment of Alzheimer’s disease. Continue Reading
December 13, 2023
The Harrington Family has been recognized in Cleveland Magazine's 2023 Faces of Cleveland as "The Faces of Life-Saving New Medicines" Continue Reading
December 08, 2023
Similar technology is gaining regulatory approval to treat sickle cell disease and drawing research attention to treat a wide range of health concerns Continue Reading
December 05, 2023
New cause of diabetes discovered, offering potential target for new classes of drugs to treat the disease Continue Reading
September 29, 2023
Aleta hopes to initiate the registrational trial investigating ALETA-001 in B-cell malignancies in 2024/25. Continue Reading